Investigation of hypoglycemic, hypolipidemic and anti-nephritic activities of Paecilomyces tenuipesN45 in diet/streptozotocin-induced diabetic rats

CHUNGANGLIU1, XUERUIZENGG1, YIL1, HONGLIMA1, JINGJINGSONG1, YUHUANLI1, YULINZHOU1, ROBERTJ.LEE1,2 and DIWANG1,3

1School of Life Sciences, Jilin University, Changchun, Jilin 130012, P.R. China; 2Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA; 3Zhuhai College of Jilin University, Jilin University, Zhuhai, Guangdong 519041, P.R. China

Received December 25, 2015; Accepted February 2, 2017

DOI: 10.3892/mmr.2017.6311

Abstract. Due to its pharmacological activities, Paecilomyces tenuipes has previously been used as a folk medicine in Asia. The primary aim of the present study was to investigate the hypoglycemic, hypolipidic and anti-nephritic effects of P. tenuipes N45 aqueous extracts (PTNE) in a high fat diet/streptozotocin-induced diabetic rat model. The rats were treated with 120 mg/kg of metformin or 0.04, 0.2 or 1.0 g/kg PTNE for 4 weeks. The hypoglycemic activity of PTNE was confirmed by the observation of reduced fasting blood glucose level and by partially normalized oral glucose tolerance. PTNE reduced total cholesterol and triglyceride content, and balanced the levels of low-density and high-density lipoproteins. The suppressive effects of PTNE on creatinine, blood urea nitrogen, interleukin (IL)-2, IL-6 and nuclear factor-κB levels indicated its ability to provide protection against diabetic nephropathy. PTNE treatment increased superoxide dismutase, malondialdehyde and glutathione peroxidase levels, suggesting that its anti-diabetic and anti-nephrotic activities may be associated with the prevention of oxidative damage during type 2 diabetic mellitus. The findings of the present study provided experimental evidence for the application of Paecilomyces tenuipes N45 on the treatment of type 2 diabetic mellitus.

Introduction

Diabetes mellitus, as a chronic endocrine metabolic disease with a high incidence of complications, is a major health risk worldwide (1). As a chronic disease, micro- and macro-vascular complications frequently occur in patients suffering from diabetes mellitus. In addition, complex metabolic disorders involving lipids, carbohydrates and proteins are frequently observed (2). Patients with type 2 diabetes mellitus present with a more aggressive course of disease, and an increased risk for early hypertension and nephropathy compared with patients with type 1 diabetes mellitus. A combination of increased blood glucose levels and organ damage caused by insulin secretion deficiency can result in various pathological complications, including nephropathy (3). Diabetic nephropathy has been demonstrated to be caused by chronic inflammation (4). Activation of nuclear factor-κB (NF-κB) was demonstrated to be involved in the pathogenesis of diabetic nephropathy (5).

Standard therapies for diabetes focus on blood glucose regulation and often fail to control the associated complications (6). Certain widely used medications for diabetic management have demonstrated undesirable adverse effects, making further searching for safer and more efficacious treatments of diabetes mellitus urgently required.

Herbal medicines have demonstrated anti-diabetic activities and the ability to reduce diabetic complications (7). For example, Cordyceps militaris polysaccharide-enriched fraction was revealed to have a hypoglycemic effect on diabetic rats (8). Paecilomyces tenuipes, a well-known Chinese medicinal entomopathogenic fungus, has a long history of medicinal use in Asia (9). The anti-depressant, anti-tumor and immunomodulatory activities of P. tenuipes have been confirmed in previous studies (10,11). Furthermore, P. tenuipes has been demonstrated to improve lipid profiles and lipid peroxidation (12). An improved mutant strain named P. tenuipes N45, with an elevated growth rate and polysaccharide content, was obtained via chemical mutagenesis in the present study. The strain has been successfully preserved in the China Center for Type Culture Collection (CCTCC; no. M2011145). P. tenuipes N45 has previously been
demonstrated to have anti-hyperglycemic, anti-hyperlipidemic and anti-oxidant effects in alloxan-induced diabetic rats (13). Diabetes mellitus caused by alloxan, which destroys the β cells of the pancreas, is pathologically similar to type 1 diabetes mellitus (14,15). It was therefore hypothesized that P. tenuipes N45 may display similar beneficial effects on type 2 diabetes mellitus.

The present study aimed to investigate the hypoglycemic, hypolipidemic and anti-inflammatory activities of P. tenuipes N45 aqueous extract (PTNE) in a high-fat diet and streptozotocin (STZ)-induced rat model. Following 4 weeks of treatment with PTNE, several indexes associated with oxidation resistance, hypoglycemic, hypolipidemic and anti-nephropathy activities were measured. These data supported the potential use of PTNE as an adjuvant therapy for type 2 diabetes mellitus.

Materials and methods

Submerged fermentation of P. tenuipes N45. Spores collected from cultured P. tenuipes Pt 196 (RCEF 4339; Anhui Agricultural University, Anhui, China) were washed twice with phosphate buffered saline (PBS) and adjusted to 1x10⁷/ml. The spores were incubated in 1 mg/ml nitrosoguanidine PBS solution at 25°C for 12 min and then cultured in solid potato dextrose agar medium 96-well plates. For the selection of mutants, individual strains were cultured in 250 ml flasks. By comparing the dry mycelium weight and contents of effective components (adenosine and polysaccharide) of three consecutive cultivated generations, P. tenuipes N45 (CCTCC no. M2011145) was obtained as the optimal strain. P. tenuipes N45 was cultured in a rotary shaker incubator (10 L, Biostat B; Germany) at 150 rpm for 5 days, and the temperature was maintained at 26°C. The culture medium contained following ingredients: 40 g/l glucose, 10 g/l peptone and 10 g/l yeast extract powder. Mycelium pellets were harvested and lyophilized for further usage.

Crude extract preparation. PTNE was prepared as follows: 100 g mycelial powder was extracted twice in 5 L double distilled water at 80°C for 3 h. Following centrifugation at 3,500 x g for 10 min, the supernatant was evaporated under reduced pressure at 55°C in a rotary evaporator. The extract was subsequently freeze-dried for further experiments.

Diet/STZ-induced diabetic rat model and drug administration procedure. The following experimental protocol was approved by the Institution Animal Ethics Committee of Jilin University (Changchun, China). A total of 60 Sprague-Dawley male rats (SCXX (J1)-2011-0003) (purchased from Norman Bethune University of Medical Science Jilin University, Jilin, China) were maintained on a 12-h light/dark cycle (lights on 07:00-19:00) at 23±1°C with water and food available ad libitum.

Rats were fed with standard laboratory diet for 2 weeks. Subsequently, 50 rats weighing 260-300 g were selected for the present study. To induce diabetes, 50 rats were fed with a high fat diet (68.8% standard chow, 20% sucrose, 10% lard, 0.2% cholesterol and 1% salt mixture, purchased from the Lab Animal Center of Jilin University, Jilin, China) for 8 weeks, followed with intraperitoneal injection of 30 mg/kg STZ once per day for 3 days (16). Rats injected with citrate buffer only were used as the control (n=10). During the experiment, rats were fed with 5% glucose solution for 4 h following STZ injection to prevent hypoglycemia. Rats with fasting serum glucose levels between 11 and 26 mmol/l were placed in the diabetic groups. The diet/STZ-induced diabetic rats were randomly separated into five groups and injected with 10 ml/kg physiological saline (model group; MD; n=10), 120 mg/kg metformin (Met; positive control group; n=10; met purchased from Beijing Jingfeng Zhiyao Co., Ltd., Beijing, China) and 0.04, 0.2 or 1.0 g/kg PTNE (n=10/group) for 4 continuous weeks. Bodyweight was recorded for the duration of the experiment, and fasting blood glucose was monitored using a Glucose Assay kit (Nanjing KeyGen Biotech Co. Ltd., Nanjing, China) on day 28 after PTNE treatment, following 18 h food deprivation.

Oral glucose tolerance test (OGTT). Following 4 weeks of treatment, an OGTT was performed on the diabetic rats. Following 12 h fasting, rats were orally treated with physiological saline, 120 mg/kg Met or 0.04, 0.2 or 1.0 g/kg PTNE. After 30 min, 2.0 g/kg glucose was administered orally to each rat. Blood samples were collected at 0, 0.5, 1 and 2 h, and plasma glucose concentrations were measured. The area under the blood glucose curve (AUC) was calculated according to the following equation (13): AUC = (basal glycemia + glycemia 0.5 h) x0.25+(glycemia 0.5 h + glycemia 1 h) x0.25 +(glycemia 1 h + glycemia 2 h) x0.5.

Biochemical index analysis. Prior to sacrifice, blood was sampled from the hearts of all the rats, which were placed under anesthesia. Superoxide dismutase (SOD; cat. no. A001-3), glutathione peroxidase (GSH-Px; cat. no. A005), malondialdehyde (MDA; cat. no. A003-4), low-density lipoprotein cholesterol (LDL-C; cat. no. A113-1), high density lipoprotein cholesterol (HDL-C; cat. no. A113-2), total cholesterol (TC; cat. no. A111-1), triglycerides (TG; cat. no. A110-1), blood urea nitrogen (BUN; cat. no. C013-2) and creatinine (Cr; cat. no. C011-2) levels were analyzed using commercial kits (Nanjing KeyGen Biotech Co., Ltd., Nanjing, China). The levels of insulin (cat. no. CK-E30620), interleukin 2 (IL-2; cat. no. CK-E30648), interleukin 6 (IL-6; cat. no. CK-E30646), NF-κB (cat. no. CK-E91672R) and tumor necrosis factor-β (TNF-β; cat. no. CK-E30527) were measured using the enzyme-linked immune sorbent assay method (Shanghai Yuan Ye Biotechnology Co. Ltd., Shanghai, China).

Statistical analysis. All data were expressed as the mean ± standard error of the mean. Statistical significance was determined by a one-way analysis of variance followed by post-hoc multiple comparisons with Dunn’s test, using SPSS 16.0 software (SPSS, Inc., Chicago, IL, USA). P≤0.05 was considered to indicate a statistically significant difference.

Results

Hypoglycemic effects of PTNE in diabetic rats. Changes in bodyweight, fasting blood glucose and serum insulin levels were measured to investigate the hypoglycemic effects of
PTNE. Compared with the control group, decreased body-weight and serum insulin levels and increased fasting blood glucose concentration were observed in diet/STZ-induced diabetic rats (P<0.01; Table I). Normal body weight, insulin and fasting blood glucose levels were partially restored following 4 weeks of Met administration compared with the model group (P<0.01; Fig. 1 and Table I). Similarly, PTNE treatment improved the body weight of diabetic rats, especially following 4 weeks of treatment (P<0.05; Table I). Compared with the model group, 1 g/kg PTNE treatment increased serum insulin levels by ~41.5% (P<0.01; Fig. 1A). The fasting blood glucose concentration in the model group was increased by 11.1 mmol/l compared with the control group (P<0.01; Fig. 1B) but 1 g/kg PTNE treatment suppressed the fasting blood glucose levels by 58.7% compared with the model group (P<0.01; Fig. 1B).

OGTT was used as a second diagnostic index to further confirm the hypoglycemic activities of PTNE. A significantly increased fasting blood glucose concentration was observed in diet/STZ-induced diabetic rats (P<0.01; Table I). Normal body weight, insulin and fasting blood glucose levels were partially restored following 4 weeks of Met administration compared with the model group (P<0.01; Fig. 1 and Table I). Similarly, PTNE treatment improved the body weight of diabetic rats, especially following 4 weeks of treatment (P<0.05; Table I). Compared with the model group, 1 g/kg PTNE treatment increased serum insulin levels by ~41.5% (P<0.01; Fig. 1A). The fasting blood glucose concentration in the model group was increased by 11.1 mmol/l compared with the control group (P<0.01; Fig. 1B) but 1 g/kg PTNE treatment suppressed the fasting blood glucose levels by 58.7% compared with the model group (P<0.01; Fig. 1B).

Hypolipidemic effects of PTNE in diabetic rats. Compared with the control group, TC (Fig. 3A), TG (Fig. 3B) and LDL-C levels (Fig. 3C) were increased in the model group (P<0.05), and HDL-C levels were decreased in the model group compared with the control group (P<0.05, Fig. 3D). Treatment with 120 mg/kg Met significantly reduced TC and LDL-C serum levels compared with the model group (P<0.05), but failed to alter the levels of TG and HDL-C compared with the model group. However, PTNE treatment decreased TC, TG and LDL-C levels compared with the model group (Fig. 3A-C) and reversed the suppression of HDL-C levels in the serum of the model group (P<0.05; Fig. 3D).

Anti-oxidative effects of PTNE in diabetic rats. Nutritional factors, including antioxidants, influence the management of diabetes mellitus and its complications (17). An imbalance between oxidative stress and antioxidative defense in diabetics accelerates diabetic complications (18). SOD and GSH-Px...
activity levels were decreased in the model group compared with the control group (P<0.05; Table I), and overproduction of MDA serum levels were increased in the model group compared with the control group (P<0.05; Table II). Similar to Met treatment, PTNE partially restored SOD, GSH-Px and MDA serum levels, especially at the dose of 1 g/kg (P<0.05; Table II).

**Anti-nephropathic effects of PTNE in diabetic rats.** BUN and Cr are recognized as sensitive indexes for kidney injury (19) and BUN and Cr levels were significantly increased in the model group compared with the control group (P<0.05; Fig. 4A and B). Treatment with Met and PTNE for 4 weeks significantly attenuated this increase in BUN (P<0.05; Fig. 4A) and Cr (P<0.05; Fig. 4B). Severe inflammation occurred in the model group and was characterized by the release of multiple inflammatory factors, including increased serum levels of IL-2 (P<0.05; Fig. 4C), IL-6 (P<0.05; Fig. 4D) and TNF-β (P<0.05; Fig. 4E) compared with the control group. Met and PTNE treatment significantly suppressed these indexes, with IL-2 (Fig. 4C) IL-6 (Fig. 4D) and TNF-β (Fig. 4E) serum levels significantly decreased compared
Table II. Met and PTNE treatment increased SOD and GSH-Px activity, and reduced MDA serum levels of DM rats.

<table>
<thead>
<tr>
<th>Group</th>
<th>SOD (µ/ml)</th>
<th>GSH-Px (µmol/l)</th>
<th>MDA (nmol/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>368.4±30.4</td>
<td>246.9±17.7</td>
<td>6.2±1.5</td>
</tr>
<tr>
<td>DM</td>
<td>196.3±18.5&lt;sup&gt;b&lt;/sup&gt;</td>
<td>176.1±22.3&lt;sup&gt;a&lt;/sup&gt;</td>
<td>23.5±4.9&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Met (120 mg/kg)</td>
<td>316.5±30.9&lt;sup&gt;d&lt;/sup&gt;</td>
<td>254.5±27.1&lt;sup&gt;c&lt;/sup&gt;</td>
<td>9.7±3.1&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>PTNE (g/kg)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.04</td>
<td>256.1±24.6</td>
<td>241.6±15.5&lt;sup&gt;c&lt;/sup&gt;</td>
<td>25.3±3.7</td>
</tr>
<tr>
<td>0.20</td>
<td>280.9±13.4&lt;sup&gt;c&lt;/sup&gt;</td>
<td>202.6±17.2</td>
<td>22.4±4.6</td>
</tr>
<tr>
<td>0.10</td>
<td>264.5±17.5&lt;sup&gt;c&lt;/sup&gt;</td>
<td>218.1±10.8</td>
<td>11.7±1.7&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

Data were expressed as the mean ± standard error of the mean (n=10/group). *P<0.05 and *P<0.01 vs. control. *P<0.05 and *P<0.01 vs. DM group. Met, metformin; PTNE, *Paecilomyces tenuipes* N45 water extracts; SOD, superoxide dismutase; GSH-Px, glutathione peroxidase; MDA, methane dicarboxylic aldehyde; DM, diet/streptozotocin-induced diabetic rat model.

Figure 4. Anti-nephropathic effects of PTNE treatment in DM rats. The serum levels of (A) BUN, (B) Cr, (C) IL-2, (D) IL-6, (E) TNF-β and (F) NF-κB were determined via ELISA. Data are expressed as the mean ± standard error of the mean (n=10). *P<0.05 and **P<0.01 vs. ctrl; *P<0.05 and **P<0.01 vs. DM group. PTNE, *Paecilomyces tenuipes* N45 water extracts; DM, diet/STZ-induced diabetic rat model; BUN, blood urea nitrogen; Ctrl, control; DM, diet/STZ-induced diabetic rat model; Met, metformin; PTNE, *Paecilomyces tenuipes* N45 water extracts; HFHSD, high fat and high sucrose diet; STZ, streptozotocin; Cr, creatinine; IL, interleukin; TNF-β: tumor necrosis factor-β; NF-κB: nuclear factor-κB.
with the model group (P<0.05). Notably, 120 mg/kg Met and 1.0 g/kg PTNE treatment decreased NF-kB serum levels by 20.5 and 17.8%, respectively, compared with the model group (P<0.05; Fig. 4F).

**Discussion**

The rat model of diabetes, induced by a high-fat diet and a low dose of STZ, displays similar metabolic features to those of human type 2 diabetes mellitus (20), which is a complex and heterogeneous disorder associated with a progressive decline in insulin action.

Previous research has focused on the use of traditional folk medicines produced from natural plants, which has resulted in significant developments in functional food, nutraceuticals and pharmaceuticals (21,22). In contrast to the majority of treatments used to manage diabetes, as a crude fungus, *P. tenuipes* contains a complex mixture of bioactive components, which have multiple molecular targets. This multipronged targeting approach may reduce hyperglycemia, inflammation and oxidative stress in a more natural way, and may result in fewer adverse side effects. Based on the findings of the present study and its toxicological profile (23), *P. tenuipes* N45 has been demonstrated to be both safe and effective.

As an agent for inducing diabetes, STZ causes β-cell injury in the pancreas (24). The pancreas is responsible for regulating serum glucose concentration. The anti-hyperglycemic activity of natural products usually occurs due to the restoration of pancreatic function via the enhancement of insulin secretion (7). In the present study, PTNE increased serum insulin levels and demonstrated positive activity on OGTT, which is an important index for evaluating islet function (25). The beneficial effect on pancreatic function may be an important contributor to the hypoglycemic effect of PTNE.

Altered lipid metabolism, including changes in TG, TC, HDL-C and LDL-C levels, are observed in type 2 diabetes mellitus (26). This is a risk factor for coronary heart disease (27). PTNE may be beneficial in preventing coronary heart disease and atherosclerosis via the regulation of lipid metabolism. During development of diabetes mellitus, insulin resistance is responsible for the release of adipocytokines and relaxation of the afferent arteriole. The risk of the development of atherosclerosis in diabetes mellitus can be reduced by elevating HDL-C levels (28). On the other hand, diabetes-associated dyslipidemia results in lipid accumulation in the kidney, which leads to insulin resistance, inflammation and oxidative stress (29). The antilipemic effects of PTNE may be involved in its anti-diabetic and anti-nephropathic activities.

Diabetic nephropathy represents a risk factor for mortality, including cardiovascular mortality (30). Suppressed BUN and creatinine levels, which are important markers of kidney damage, were observed in PTNE-treated diabetic rats. It has previously been reported that chronic inflammation during the development of diabetes contributes to nephropathy (31). Interleukins, especially IL-2 and IL-6, are involved in glomerular damage (32). Furthermore, high glucose levels initiate an inflammatory response characterized by the activation of the pro-inflammatory NF-κB pathway, which promotes the expression and activity of its downstream inflammatory mediators (33). Based on the results of the present study, the renal protective activity of PTNE against diabetic nephropathy has been confirmed.

Hyperglycemia leads to accumulation of ROS, which in turn mediate various metabolic defects associated with the diabetic state (29). An imbalance between oxidative stress and antioxidative defense in diabetes results in cell and tissue damages and accelerate diabetic complications (18). SOD and GSH-Px are regarded as the primary defense systems against ROS generation (34). MDA is a major product of lipid peroxidation, and low levels of MDA suggest reduced lipid peroxidation and weaker oxidant stress (32). Anti-oxidant agents are emerging as potential agents for preventing pancreatic β cell destruction (28). Therefore, the antioxidative effects of PTNE may be another important contributor to its modulation of blood glucose and lipid metabolism and inflammation.

In summary, in diet/STZ-induced diabetic rats, the hypolipidemic, hypoglycemic and anti-diabetic nephritic effects of PTNE have been confirmed. Previous data suggest that all these effects may be associated with the modulation of oxidative damages by PTNE. The findings of the present study support the use of PTNE as a pharmaceutical agent for the management of diabetes and diabetic complications.

**Acknowledgements**

The present study was supported by the Science and Technology Key Project in Jilin Province of China (grant nos. 20140311072YY, 20150203002NY, 20160520036JH and 20160204029YY).

**References**